London, Jan 31, 2026, 09:29 GMT — The market has closed.
Haleon’s stock climbed 2% on Friday, finishing at 379 pence, outpacing the wider London market as the month closed strong.
The significance of this move lies in the FTSE 100 marking its seventh consecutive month of gains — its longest winning streak since more than 12 years ago — putting UK global stocks under the spotlight as February approaches. “The weaker pound is obviously beneficial for the multinationals,” said Fiona Cincotta, senior market analyst at City Index. Reuters
As the market reopens Monday, traders will watch currency fluctuations and rate forecasts closely, following a late-January rally that lifted London equities to new highs.
Hargreaves Lansdown reported that Haleon’s shares fluctuated between 371.1 pence and 379.3 pence on Friday, with around 14.1 million shares changing hands. The stock’s 52-week range sits between a low of 325.1 pence and a high of 419.4 pence.
Haleon is set to release its full-year 2025 results on Feb. 25, with a first-quarter trading update scheduled for April 29, the company’s events calendar shows.
In a filing from January, Haleon revealed intentions to overhaul its operating model—covering market execution and global functions. The plan includes establishing a chief growth officer position and dividing certain regions into fresh operating units. CEO Brian McNamara described the shift as a move toward “a simpler and more agile and efficient organisation.” OTC Markets
That shifts more focus onto the February results, as investors look for details on how the reorganisation will impact execution and costs, beyond the initial overview.
Healthcare stocks mostly edged higher on Friday, led by GSK, which climbed 1.3% in London.
Haleon’s recent rebound feels temporary in a stock known for swift shifts tied to guidance. Come February, any hint of slowing volumes, toughening pricing, or persistent cost pressures could erase these gains fast.
